{"disease":{"id":"waldenstrom-macroglobulinemia","name":"waldenstrom macroglobulinemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00039676","title":"Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1836,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00923507","title":"Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03740529","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":803,"lead_sponsor_name":"Loxo Oncology, Inc.","has_results":false},{"nct_id":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03521596","title":"Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT01416428","title":"Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":210,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03162536","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":190,"lead_sponsor_name":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT04830046","title":"Covid-19 Vaccine Responsiveness in MM and Waldenstrom","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02952508","title":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Cellectar Biosciences, Inc.","has_results":false},{"nct_id":"NCT01351935","title":"Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT01076543","title":"Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06547866","title":"Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":102,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT06151730","title":"Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04116437","title":"Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04840602","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03833180","title":"A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT01251575","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02332980","title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT00422799","title":"Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT04775745","title":"Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT00697346","title":"Study of MLN8237 in Participants With Advanced Hematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01075321","title":"Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT06561347","title":"Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02962401","title":"Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT03820817","title":"Rifaximin in Patients With Monoclonal Gammopathy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT01479842","title":"Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Kami Maddocks, MD","has_results":false},{"nct_id":"NCT04440059","title":"A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT04260217","title":"APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00492050","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04273139","title":"Ibrutinib + Venetoclax in Untreated WM","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT01129193","title":"AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Amir Mortazavi","has_results":false},{"nct_id":"NCT05914662","title":"Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05734495","title":"Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT01261247","title":"Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT06860880","title":"Combating Cancer-Related Fatigue: A Personalized Supportive Care Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07231952","title":"A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03037645","title":"Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"Sunesis Pharmaceuticals","has_results":false},{"nct_id":"NCT07420959","title":"ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05190705","title":"Loncastuximab Tesirine in WM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Shayna Sarosiek, MD","has_results":false},{"nct_id":"NCT03015896","title":"Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"David Bond, MD","has_results":false},{"nct_id":"NCT03192397","title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01567709","title":"Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02677324","title":"Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT02339922","title":"Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03771157","title":"Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"University of Rochester","has_results":true},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}